Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

4.9K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.2K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

6.9K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.2K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.2K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

8.8K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

7.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of the gene cluster for the dithiolopyrrolone antibiotic holomycin in Streptomyces clavuligerus.

Proceedings of the National Academy of Sciences of the United States of America·2010
Same author

Safety evaluation of tea (Camellia sinensis (L.) O. Kuntze) flower extract: assessment of mutagenicity, and acute and subchronic toxicity in rats.

Journal of ethnopharmacology·2010
Same author

Influences of soil properties and leaching on nickel toxicity to barley root elongation.

Ecotoxicology and environmental safety·2010
Same author

Effects of CO2 insufflation on cerebrum during endoscopic thyroidectomy in a porcine model.

Surgical endoscopy·2010
Same author

Plants' use of different nitrogen forms in response to crude oil contamination.

Environmental pollution (Barking, Essex : 1987)·2010
Same author

Overexpression of p35 in Min6 pancreatic beta cells induces a stressed neuron-like apoptosis.

Journal of the neurological sciences·2010

Related Experiment Video

Updated: Nov 28, 2025

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

9.8K

Mutant p53 in Cancer Progression and Targeted Therapies.

Gaoyang Zhu1, Chaoyun Pan2, Jin-Xin Bei3

  • 1Postdoctoral Research Center, Shunde Hospital, Southern Medical University (The First People's Hospital of Shunde), Foshan, China.

Frontiers in Oncology
|November 26, 2020
PubMed
Summary
This summary is machine-generated.

Mutant TP53 proteins drive cancer by losing tumor suppression and gaining oncogenic functions. This review explores targeting these mutant p53 gain-of-functions with emerging therapies like gene editing and immunotherapies.

Keywords:
drug resistancegain-of-functionmutant p53 proteintargeted therapytumorigenesis

More Related Videos

Purification of Ubiquitinated p53 Proteins from Mammalian Cells
10:55

Purification of Ubiquitinated p53 Proteins from Mammalian Cells

Published on: March 21, 2022

2.5K
Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

2.0K

Related Experiment Videos

Last Updated: Nov 28, 2025

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

9.8K
Purification of Ubiquitinated p53 Proteins from Mammalian Cells
10:55

Purification of Ubiquitinated p53 Proteins from Mammalian Cells

Published on: March 21, 2022

2.5K
Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

2.0K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • TP53 is the most frequently mutated tumor suppressor gene in human cancers.
  • Most TP53 mutations result in full-length mutant p53 proteins with altered functions.
  • Mutant p53 proteins exhibit both loss of tumor suppressive functions and acquisition of oncogenic gain-of-functions (GOF).

Purpose of the Study:

  • To review recent advances in understanding the oncogenic GOF of mutant p53 (Mutp53).
  • To summarize potential therapeutic strategies targeting Mutp53 in human cancers.

Main Methods:

  • Literature review of recent advances in Mutp53 research.
  • Discussion of current clinical trials and emerging therapeutic strategies.

Main Results:

  • Mutp53 proteins promote tumorigenesis through GOF.
  • Several therapeutic strategies are under investigation, including gene editing, peptide-mediated restoration, and immunotherapy.

Conclusions:

  • Targeting Mutp53 GOF represents a promising therapeutic avenue for human cancers.
  • Emerging strategies like CRISPR/Cas9, peptide restoration, and immunotherapies offer new hope for treating TP53-mutated cancers.